Effect of a novel covalent antithrombin-heparin complex on thrombin generation on fetal distal lung epithelium

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 274, Issue 6 18-6, 1998, Pages

  Chan, A K C ^a   Berry, Leslie ^c   Mitchell, Lesley ^c   Baranowski, Bryan ^c   O'Brodovich, Hugh ^a,b   Andrew, Maureen ^a,c,d  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

Anticoagulant; Bronchopulmonary dysplasia; Respiratory distress syndrome; Tissue factor

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN HEPARIN COMPLEX; BLOOD CLOTTING FACTOR 7; FIBRIN; PROTHROMBIN; THROMBIN; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FETUS; LUNG ALVEOLUS EPITHELIUM; LUNG DYSPLASIA; NONHUMAN; PREMATURITY; PRIORITY JOURNAL; RAT; RESPIRATORY DISTRESS SYNDROME;

EID: 0031776026     PISSN: 10400605     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajplung.1998.274.6.l914     Document Type: Article

References (45)

1. Andrew, M., L. Berry, and H. O'Brodovich. Thrombin inhibition by fetal distal lung epithelium is different in fetal and adult plasma. Am. J. Respir. Cell Mol. Biol. 11: 35-41, 1994.
2. Bachofen, M., and E. Weibel. Structural alterations of lung parenchyma in the adult respiratory distress syndrome. Clin. Chest Med. 3: 35-56, 1982.
3. Bajaj, M., M. Kuppuswamy, H. Saito, S. Spitzer, and S. Bajaj. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. Proc. Natl. Acad. Sci. USA 87: 8869-8873, 1990.
4. Bauer, K., L. Weiss, D. Sparrow, P. Vokonas, and R. Rosenberg. Aging-associated changes in indices of thrombin generation and protein C activation in humans. J. Clin. Invest. 80: 1527-1534, 1987.
5. Berry, L., M. Andrew, M. Post, F. Ofosu, and H. O'Brodovich. A549 lung epithelial cells synthesize anticoagulant molecules on the cell surface and matrix and in conditioned media. Am. J. Respir. Cell Mol. Biol. 4: 338-346, 1991.
6. Blombäck, B., and M. Blombäck. The molecular structure of fibrinogen. Ann. NY Acad. Sci. 202: 77-97, 1972.
7. Broze, G. J. Tissue factor pathway inhibitor. Thromb. Haemost. 74: 90-93, 1995.
8. Chan, A. K., L. Berry, H. O'Brodovich, P. Klement, M. Mitchell, and M. Andrew. Covalent antithrombin-heparin complexes with high anticoagulant activity: intravenous, subcutaneous and intratracheal administration. J. Biol. Chem. 272: 22111-22117, 1997.
9. Coalson, J., V. Winter, D. Gerstmann, S. Idell, R. King, and R. Delemos. Pathophysiologic, morphometric and biochemical studies of the premature baboon with bronchopulmonary dysplasia. Am. Rev. Respir. Dis. 145: 872-881, 1992.
10. 2 into the rat lung. Am. J. Pathol. 137: 883-894, 1990.
11. Fukuda, Y., M. Ishizaki, Y. Masuda, G. Kimura, O. Kawanami, and Y. Masugi. The role of intraalveolar fibrosis in the process of pulmonary structural remodeling in patients with diffuse alveolar damage. Am. J. Pathol. 126: 171-182, 1987.
12. Gajl-Peczalska, K. Plasma protein composition of hyaline membrane in the newborn as studies by immunofluorescence. Arch. Dis. Child. 39: 226-231, 1964.
13. Girard, T. J., L. A. Warren, W. F. Novotny, K. M. Likert, S. G. Brown, J. P. Miletich, and G. J. Broze. Functional significance of the Kunitz type inhibitor domains of lipoprotein associated coagulation inhibitor. Nature 338: 518-520, 1989.
14. Gitlin, D., and J. Craig. The nature of the hyaline membrane in asphyxia of the newborn. Pediatrics 17: 64-71, 1956.
15. Gorenflo, M., M. Vogel, L. Herbst, C. Bassir, E. Kattner, and M. Obladen. Influene of clinical and ventilatory parameters on morphology of bronchopulmonary dysplasia. Pediatr. Pulmonol. 19: 214-220, 1995.
16. Gross, T. J., R. H. Simon, and R. G. Sitrin. Tissue factor procoagulant expression by rat alveolar epithelial cells. Am. J. Respir. Cell Mol. Biol. 6: 397-403, 1992.
17. Guha, A., R. Bach, W. Konigsberg, and Y. Nemerson. Affinity purification of human tissue factor: interaction of factor VII and tissue factor in detergent micelles. Proc. Natl. Acad. Sci. USA 83: 299-302, 1986.
18. Hatton, M., S. Moar, and M. Richardson. Evidence that rabbit 125-I-antithrombin III binds to proteoheparan sulphate at the subendothelium of the rabbit aorta in vitro. Blood Vessels 25: 12-27, 1988.
19. Jaques, L. B., J. Mahadoo, and L. W. Kavanagh. Intrapulmonary heparin. A new procedure for anticoagulant therapy. Lancet 2: 1157-1161, 1976.
20. Jobe, A. H. Pulmonary surfactant therapy. N. Engl. J. Med. 328: 861-868, 1993.
21. Liechty, E. A., E. Donovan, and D. Purohit. Reduction of neonatal mortality after multiple doses of bovine surfactant in low birth weight neonates with respiratory distress syndrome. Pediatrics 88: 19-28, 1991.
22. Lindahl, A. L., P. B. Jacobsen, P. M. Sandset, and U. Abilgaard. Tissue factor pathway inhibitor with high anticoagulant activity is increased in post-heparin plasma and in plasma from cancer patients. Blood Coagul. Fibrinolysis 2: 713-721, 1991.
23. Long, W., T. Thompson, and H. Sundell. Effects of two rescue doses of a synthetic surfactant on mortality rate and survival without bronchopulmonary dysplasia. J. Pediatr. 118: 595-605, 1991.
24. Mann, K. The assembly of blood clotting complexes on membranes. Trends Biochem. Sci. 12: 229-233, 1987.
25. Nemerson, Y. The reaction between bovine brain tissue factor and factors VII and X. Biochemistry 501: 601-608, 1966.
26. Nemerson, Y. Tissue factor and hemostasis. Blood 71: 1-8, 1988.
27. Nemerson, Y., and D. Repke. Tissue factor accelerates the activation of coagulation factor VII: the role of a bifunctional coagulation factor. Thromb. Res. 40: 351-358, 1985.
28. Novotny, W., T. Girard, J. Miletich, and G. J. Broze. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J. Biol. Chem. 264: 18832-18837, 1989.
29. O'Brodovich, H., L. Berry, M. D'Costa, R. Burrows, and M. Andrew. The influence of fetal pulmonary epithelium on thrombin activity. Am. J. Physiol. 261 (Lung Cell. Mol. Physiol. 5): L262-L270, 1991.
30. O'Brodovich, H., B. Rafii, and M. Post. Bioelectric properties of fetal alveolar epithelial monolayers. Am. J. Physiol. 258 (Lung Cell. Mol. Physiol. 2): L201-L206, 1990.
31. O'Brodovich, H., J. Weitz, and F. Possmayer. Effect of fibrinogen degradation products and lung ground substance on surfactant function. Biol. Neonate 57: 325-333, 1990.
32. Ofosu, F., P. Sie, G. Modi, F. Fernandez, M. Buchanan, M. Blajchman, B. Boneu, and J. Hirsh. The inhibition of thrombin-dependent positive-feedback reactions is critical to the expression of the anticoagulant effect of heparin. Biochem. J. 243: 579-588, 1987.
33. Olson, S. T., I. Björh, R. Sheffer, P. A. Craig, and J. Choay. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J. Biol. Chem. 267: 12528-12538, 1992.
34. Østerud, B., and S. Rapaport. Activation of factor IX by the reaction product of tissue factor and factor VII. Additional pathway for initiating blood coagulation. Proc. Natl. Acad. Sci. USA 74: 5260-5264, 1977.
35. Rao, L., and S. Rapaport. Activation of factor VII bound to tissue factor: a key early step in the tissue factor pathway of blood coagulation. Proc. Natl. Acad. Sci. USA 85: 6687-6691, 1988.
36. Sabharwal, A. K., S. P. Bajaj, S. Tricomi, A. Ameri, T. M. Hyers, T. E. Dahms, F. B. Taylor, and M. S. Bajaj. Tissue factor pathway inhibitor and von Willebrand factor antigen levels in adult respiratory distress syndrome and in a primate model of sepsis. Am. J. Respir. Crit. Care Med. 151: 758-767, 1995.
37. Saldeen, T. Fibrin-derived peptides and pulmonary injury. Ann. NY Acad. Sci. 384: 319-331, 1982.
38. Sandset, P. M. Tissue factor pathway inhibitor (TFPI) - an update. Haemostasis 26: 154-165, 1996.
39. Sandset, P. M., B. J. Warn-Cramer, S. L. Maki, and S. I. Rapaport. Immunodepletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant. Proc. Natl. Acad. Sci. USA 88: 708-712, 1991.
40. Schmidt, B., F. Ofosu, L. Mitchell, L. Brooker, and M. Andrew. Anticoagulant effects of heparin in neonatal plasma. Pediatr. Res. 25: 405-408, 1989.
41. Seegers, W., G. Stohr, and H. Wolf. Alteration of surfactant function due to protein leakage: special interaction with fibrin monomer. J. Appl. Physiol. 58: 326-338, 1985.
42. Stelzner, T. J., R. F. O'Brien, K. Sato, and J. Weil. Hypoxia-induced increases in pulmonary transvascular protein escape in rats. J. Clin. Invest. 82: 1840-1847, 1988.
43. The OSIRIS Collaborative Group. Early versus delayed neonatal administration of a synthetic surfactant - the judgment of OSIRIS. Lancet 340: 1363-1369, 1992.
44. Werling, R. W., L. R. Zacharski, W. Kisiel, S. P. Bajaj, and V. A. Memoli. Distribution of tissue factor inhibitor in normal and malignant human tissue. Thromb. Haemost. 69: 366-369, 1993.
45. Witmer, M. R., S. J. Hadcock, S. L. Peltier, P. D. Winocour, M. Richardson, and M. W. C. Hatton. Altered levels of antithrombin III and fibrinogen in the aortic wall of the alloxan-induced diabetic rabbit: evidence of a prothrombotic state. J. Lab. Clin. Med. 119: 221-230, 1992.